| Dexter House Healthcare | |
| 120 Main Street, Malden, Massachusetts 02148 | |
| (781) 324-5600 | |
| Name | Dexter House Healthcare |
|---|---|
| Location | 120 Main Street, Malden, Massachusetts |
| Certified By | Medicare and Medicaid |
| No. of Certified Beds | 130 |
| Occupancy Rate | 50.08% |
| Medicare ID (CCN) | 225137 |
| Legal Business Name | 120 Main Street Operator Llc |
| Ownership Type | For Profit - Corporation |
| NPI Number | 1306396569 |
| Organization Name | REDWOOD ACQUISITON WEST LLC |
| Doing Business As | DEXTER HOUSE REHABILITATION AND CARE CENTER |
| Address | 120 Main St, Malden, MA 02148 |
| Phone Number | 781-324-5600 |
News Archive
High-risk adults between the ages of 55 and 80 should receive annual lung cancer screening with low-dose computed tomography, according to final recommendations from the U.S. Preventive Services Task Force being published in Annals of Internal Medicine.
Representatives of organizations and governments from 160 countries "agreed on Thursday to form a worldwide partnership to ensure tens of billions of dollars in foreign aid goes to help the neediest," Agence France-Presse reports.
Rexahn Pharmaceuticals, Inc. (NYSE Amex: RNN), a clinical stage pharmaceutical company commercializing potential best in class oncology and central nervous system (CNS) therapeutics, today announced that it has closed on its previously announced licensing and stock purchase agreements with Teva Pharmaceutical Industries Limited, a top 20 pharmaceutical company, for the development of its novel anti-cancer compound, RX-3117. RX-3117 is a small molecule, new chemical entity (NCE), nucleoside compound that has an anti-metabolite mechanism of action, and has therapeutic potential in a broad range of cancers including colon, lung and pancreatic cancer.
A major new study shows that delivering integrated mental and physical healthcare in team-based primary care settings at Intermountain Healthcare results in better clinical outcomes for patients, lower rates of healthcare utilization, and lower costs.
› Verified 1 days ago
| NPI Number | 1558890939 |
| Organization Name | 120 MAIN STREET OPERATOR LLC |
| Address | 120 Main St, Malden, MA 02148 |
| Phone Number | 781-324-5600 |
News Archive
High-risk adults between the ages of 55 and 80 should receive annual lung cancer screening with low-dose computed tomography, according to final recommendations from the U.S. Preventive Services Task Force being published in Annals of Internal Medicine.
Representatives of organizations and governments from 160 countries "agreed on Thursday to form a worldwide partnership to ensure tens of billions of dollars in foreign aid goes to help the neediest," Agence France-Presse reports.
Rexahn Pharmaceuticals, Inc. (NYSE Amex: RNN), a clinical stage pharmaceutical company commercializing potential best in class oncology and central nervous system (CNS) therapeutics, today announced that it has closed on its previously announced licensing and stock purchase agreements with Teva Pharmaceutical Industries Limited, a top 20 pharmaceutical company, for the development of its novel anti-cancer compound, RX-3117. RX-3117 is a small molecule, new chemical entity (NCE), nucleoside compound that has an anti-metabolite mechanism of action, and has therapeutic potential in a broad range of cancers including colon, lung and pancreatic cancer.
A major new study shows that delivering integrated mental and physical healthcare in team-based primary care settings at Intermountain Healthcare results in better clinical outcomes for patients, lower rates of healthcare utilization, and lower costs.
› Verified 1 days ago
| Ratings from Surveys (Inspections): | |
| Ratings from Quality Measures: | |
| Ratings from Staffing Data: | |
| Overall Rating: |
|---|
News Archive
High-risk adults between the ages of 55 and 80 should receive annual lung cancer screening with low-dose computed tomography, according to final recommendations from the U.S. Preventive Services Task Force being published in Annals of Internal Medicine.
Representatives of organizations and governments from 160 countries "agreed on Thursday to form a worldwide partnership to ensure tens of billions of dollars in foreign aid goes to help the neediest," Agence France-Presse reports.
Rexahn Pharmaceuticals, Inc. (NYSE Amex: RNN), a clinical stage pharmaceutical company commercializing potential best in class oncology and central nervous system (CNS) therapeutics, today announced that it has closed on its previously announced licensing and stock purchase agreements with Teva Pharmaceutical Industries Limited, a top 20 pharmaceutical company, for the development of its novel anti-cancer compound, RX-3117. RX-3117 is a small molecule, new chemical entity (NCE), nucleoside compound that has an anti-metabolite mechanism of action, and has therapeutic potential in a broad range of cancers including colon, lung and pancreatic cancer.
A major new study shows that delivering integrated mental and physical healthcare in team-based primary care settings at Intermountain Healthcare results in better clinical outcomes for patients, lower rates of healthcare utilization, and lower costs.
› Verified 1 days ago
| Number of Facility Reported Incidents | 0 |
| Number of Substantiated Complaints | 0 |
| Number of Fines | 1 |
| Total Amount of Fines in Dollars | $3250 |
| Number of Payment Denials | 0 |
| Total Number of Penalties | 1 |
| Experience Measure | Provider | National Avg. |
|---|---|---|
| Percentage of long-stay residents whose need for help with daily activities has increased | 20.85 | 14.46 |
| Percentage of long-stay residents who lose too much weight | 1.77 | 5.51 |
| Percentage of low risk long-stay residents who lose control of their bowels or bladder | 62.16 | 48.41 |
| Percentage of long-stay residents with a catheter inserted and left in their bladder | 0 | 1.79 |
| Percentage of long-stay residents with a urinary tract infection | 0 | 2.65 |
| Percentage of long-stay residents who have depressive symptoms | 0 | 5.05 |
| Percentage of long-stay residents who were physically restrained | 0 | 0.23 |
| Percentage of long-stay residents experiencing one or more falls with major injury | 3.69 | 3.36 |
| Percentage of long-stay residents assessed and appropriately given the pneumococcal vaccine | 79.1 | 93.87 |
| Percentage of long-stay residents who received an antipsychotic medication | 14.22 | 14.2 |
| Percentage of short-stay residents assessed and appropriately given the pneumococcal vaccine | 46.56 | 83.88 |
| Percentage of short-stay residents who newly received an antipsychotic medication | 1.55 | 1.79 |
| Percentage of long-stay residents whose ability to move independently worsened | 38.49 | 17.09 |
| Percentage of long-stay residents who received an antianxiety or hypnotic medication | 10.46 | 19.7 |
| Percentage of high risk long-stay residents with pressure ulcers | 6.71 | 7.32 |
| Percentage of long-stay residents assessed and appropriately given the seasonal influenza vaccine | 99.1 | 95.98 |
| Percentage of short-stay residents who made improvements in function | 67.63 | 67.99 |
| Percentage of short-stay residents who were assessed and appropriately given the seasonal influenza vaccine | 70.15 | 82.93 |
News Archive
High-risk adults between the ages of 55 and 80 should receive annual lung cancer screening with low-dose computed tomography, according to final recommendations from the U.S. Preventive Services Task Force being published in Annals of Internal Medicine.
Representatives of organizations and governments from 160 countries "agreed on Thursday to form a worldwide partnership to ensure tens of billions of dollars in foreign aid goes to help the neediest," Agence France-Presse reports.
Rexahn Pharmaceuticals, Inc. (NYSE Amex: RNN), a clinical stage pharmaceutical company commercializing potential best in class oncology and central nervous system (CNS) therapeutics, today announced that it has closed on its previously announced licensing and stock purchase agreements with Teva Pharmaceutical Industries Limited, a top 20 pharmaceutical company, for the development of its novel anti-cancer compound, RX-3117. RX-3117 is a small molecule, new chemical entity (NCE), nucleoside compound that has an anti-metabolite mechanism of action, and has therapeutic potential in a broad range of cancers including colon, lung and pancreatic cancer.
A major new study shows that delivering integrated mental and physical healthcare in team-based primary care settings at Intermountain Healthcare results in better clinical outcomes for patients, lower rates of healthcare utilization, and lower costs.
› Verified 1 days ago